MedPath

FUNDACION ONCOSUR

🇪🇸Spain
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

10

Active:2
Completed:2

Trial Phases

2 Phases

Phase 1:4
Phase 2:5

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials

Phase 2
5 (50.0%)
Phase 1
4 (40.0%)
phase_1_2
1 (10.0%)

Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)

Phase 2
Recruiting
Conditions
Metastatic Prostate Cancer
Interventions
First Posted Date
2024-09-03
Last Posted Date
2024-12-02
Lead Sponsor
Fundacion Oncosur
Target Recruit Count
78
Registration Number
NCT06582628
Locations
🇪🇸

Institut Català d'Oncologia (ICO), Badalona, Barcelona, Spain

🇪🇸

Consorcio Corporación Sanitaria Parc Taulí, Sabadell, Barcelona, Spain

🇪🇸

Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain

and more 9 locations

Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer

Phase 2
Terminated
Conditions
Renal Cell Carcinoma Stage IV
Renal Cell Carcinoma Stage III
Renal Cell Carcinoma Metastatic
Interventions
First Posted Date
2024-04-22
Last Posted Date
2024-04-26
Lead Sponsor
Fundacion Oncosur
Target Recruit Count
18
Registration Number
NCT06377722
Locations
🇪🇸

Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain

🇪🇸

Institut Català d'Oncologia. Idibell, L'Hospitalet de Llobregat, Barcelona, Spain

🇪🇸

Hospital Universitario de Valdecilla, Santander, Cantabria, Spain

and more 5 locations

Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)

Phase 2
Recruiting
Conditions
Prostate Cancer Metastatic
Interventions
First Posted Date
2022-10-03
Last Posted Date
2024-06-11
Lead Sponsor
Fundacion Oncosur
Target Recruit Count
42
Registration Number
NCT05563558
Locations
🇪🇸

Hospital Universitario 12 de Octubre, Madrid, Spain

Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer

Phase 1
Completed
Conditions
Triple Negative Breast Cancer
Interventions
Drug: Combination, Palbociclib + Binimetinib
First Posted Date
2020-07-31
Last Posted Date
2025-03-24
Lead Sponsor
Fundacion Oncosur
Target Recruit Count
24
Registration Number
NCT04494958
Locations
🇪🇸

Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain

🇪🇸

Hospìtal Universitario de la Princesa, Madrid, Spain

🇪🇸

Hospital Ramon y Cajal, Madrid, Spain

and more 5 locations

Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.

Phase 1
Recruiting
Conditions
Carcinoma, Small Cell Lung
Interventions
First Posted Date
2020-02-05
Last Posted Date
2023-11-18
Lead Sponsor
Fundacion Oncosur
Target Recruit Count
184
Registration Number
NCT04253145
Locations
🇪🇸

Hospital Virgen del Rocio, Sevilla, Andalucia, Spain

🇪🇸

Hospital Virgen de la Victoria, Málaga, Andalucía, Spain

🇪🇸

Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain

and more 10 locations
  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.